Relmada Therapeutics Inc. (RLMD)
NASDAQ: RLMD
· Real-Time Price · USD
0.71
0.01 (0.85%)
At close: Jun 18, 2025, 12:02 PM
0.85% (1D)
| Bid | 0.7 |
| Market Cap | 23.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.71M |
| EPS (ttm) | -2.51 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -0.74 |
| Analyst | Hold |
| Ask | 0.71 |
| Volume | 62,158 |
| Avg. Volume (20D) | 1,791,787 |
| Open | 0.70 |
| Previous Close | 0.70 |
| Day's Range | 0.67 - 0.71 |
| 52-Week Range | 0.24 - 4.47 |
| Beta | 0.66 |
About RLMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RLMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RLMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-9.03%
Relmada Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
9 months ago
+13.53%
Relmada Therapeutics shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.5 to $13.
1 month ago · seekingalpha.com
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptRelmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda...
2 months ago · seekingalpha.com
Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call TranscriptRelmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CF...